Business
TETRIS PHARMA SERVICE AGREEMENT WITH SYNEOS HEALTH
TETRIS PHARMA SERVICE AGREEMENT WITH SYNEOS HEALTH.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n \n Arecor Therapeutics plc\n \n \n \n (\"Arecor\", the \"Company\" or the \"Group\")\n \n \n \n \n \n \n \n \n \n TETRIS PHARMA SIGNS SERVICE AGREEMENT WITH SYNEOS HEALTH\n \n \n \n \n \n \n \n Cambridge, UK, 12 December 2022:\n Arecor Therapeutics plc (AIM: AREC),the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that subsidiary company, Tetris Pharma Ltd hassigned a service agreement with Syneos Health® (Nasdaq: SYNH),the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success,to support the build out of Tetris Pharma's commercial platform across Europe.\n \n \n \n \n See full Tetris Pharma announcement below:\n \n \n \n \n \n \n \n \n Tetris Pharma signs service agreement with Syneos Health\n \n \n \n \n \n \n \n \n \n Partnership to support Tetris Pharma roll-out of Ogluo® across Europe\n \n \n \n \n \n \n \n \n \n \n \n \n 12 December 2022\n \n - Tetris Pharma Ltd (\"Tetris Pharma\" or \"the Company\"), a subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC), today announces that it has signed a service agreement with Syneos Health® (Nasdaq: SYNH),\n the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success,\n to support the build out of Tetris Pharma's commercial platform across Europe.\n \n \n \n \n \n Through this partnership, Syneos Health will provide commercial support through\n an outsourced\n contract sales services to accelerate healthcare practitioner awareness of Tetris Pharma's flagship product, Ogluo®, for people living with diabetes across initial launch territories.\n \n \n \n \n \n \n Dr. Shafiq Choudhary, Managing Director, Tetris Pharma, commented:\n \n \n \n \n \n \n \n \n \"Following the recent launch of Ogluo® (glucagon prefilled autoinjector pen) in Germany, we are focused on continuing its accelerated roll-out across Europe. Syneos Health was one of several potential partners that were evaluated during the process of partnering with an organisation that would provide a multitude of commercial options to help establish the product across Europe. Partnering with Syneos Health, a leader in clinical research, medical affairs, and co...